Oxford University has stopped administering doses of the COVID-19 vaccine it developed with AstraZeneca PLC AZN,
AZN,
in a small UK study aimed at assessing its safety and effectiveness in children and adolescents, to wait to learn more about rare blood clotting problems found in a small group of adults who have it. received, the Wall Street Journal reported Tuesday. The trial began in mid-February and involved more than 200 young people aged 6 to 17. He quoted an Oxford spokesman as saying the trial had found no safety issues, but that there were wider concerns and a review of the vaccine by UK and European Union regulators. The European Medicines Agency said earlier that it expects to update the public on its investigation into the problem of blood clotting later this week.